Paxlovid tied to lower risk of hospital stay, heart problems, death in adults with kidney disease and COVID
University of Minnesota http://twin-cities.umn.edu/ 612-625-5000 The antiviral drug nirmatrelvir-ritonavir (Paxlovid) was linked to a lower risk of hospitalization within 30 days and major adverse cardiovascular events (MACEs) and death at 1 year in adults with COVID-19 and chronic kidney disease (CKD) or kidney failure, finds a study this week in Open Forum Infectious Diseases. Because patients with CKD and kidney failure were excluded from Paxlovid randomized clinical trials, researchers from Massachuset
